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Abstract
Background: Depression is a chronic non communicable disease. It is a growing public health concern with
established links with a number of co-morbidities, including diabetes mellitus. The study aimed to estimate the
prevalence of depression at a population level, establish the depression sub-population phenotypic characteristics
while exploring for links between depression and a spectrum of glycemic abnormalities.
Methods: A nationally representative cross-sectional study was conducted in Malta between 2014 and 2016.
Participants were categorized into different sub-populations according to their glycaemic status. Depression
prevalence rates and phenotypic characteristics for each sub-population were established. Multiple regression
analysis was performed to identify links with depression.
Results: Depression was prevalent in 17.15% (CI 95%: 16.01–18.36) with a female predominance. Those with known
(as opposed to newly diagnosed) diabetes had the highest depression prevalence when compared to other
glycemic sub-groups. These also exhibited a significant link with self-reported depression. However, at a population
level, depression was mostly prevalent within the normoglycaemic sub-population.
Conclusions: The study confirms the strong link between diabetes and depression, especially, in a high risk
dysglycaemic population. Of public health concern is the high depression occurrence within the normoglycaemic
sub-population, which attributed for the majority of the Maltese population. In order to reduce the impact of
mental health on the population, physicians may consider implementing depression screening clinical tools as part
of their routine health check-ups at primary care level, irrespective of the glycaemic status of their patients.
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Background
Depression is a mental health disorder and a chronic non-
communicable disease. Depression attributes to a consid-
erable global disability and burden making this disease a
public health concern [1, 2]. Across Europe the prevalence
of depression has been found to vary considerably. This
may be due to a number of contextual factors such as
demographic, environmental, cultural and economic fac-
tors [3]. Different comorbidities such as coronary heart
disease, stroke and diabetes have been found to be associ-
ated with depression [4–7]. In fact, it was reported that in-
dividuals with diabetes are two-times more likely to
develop depressive symptoms when compared to none di-
abetics [8, 9]. However, there have been contradictory
findings with regards to this depression-diabetes link [10].
Furthermore, it was reported that individuals with undiag-
nosed diabetes and impaired glucose metabolism are not
at increased risk of depression [11].
The Mediterranean region is a unique area with simi-
lar demographic and socio-economic factors. This region
was once applauded for its particular diet and the associ-
ated prevention benefits in the development of diabetes,
cardiovascular disease and obesity [12, 13]. Adherence to
the Mediterranean diet also has been associated with a
reduced risk of depression both in the young and elderly
populations [14–17]. However, the Mediterranean basin
has developed an increased type 2 diabetes prevalence
among other non-communicable diseases. A possible
reason is the dietary patterns that have since shifted to a
more Westernized pattern [18]. In fact, a number of
studies across the Mediterranean region have reported
this growing diabetes burden [19–21]. Hence, with the
shift in dietary patterns and increase in diabetes preva-
lence, it is expected that the depression rate will follow
suite among the Mediterranean region. Furthermore, the
Northern Mediterranean countries have been reported
to have industrialized characteristics while the Southern
Mediterranean countries are characterized as being simi-
lar to less developed countries. The Mediterranean
Islands, including the Maltese Islands found in the mid-
dle of the Mediterranean Sea, share a mixture of features
of both the Northern and Southern countries including
the dietary shift to a Westernized diet [22, 23]. The
Maltese Islands are made up of two islands of Malta and
Gozo occupying a small archipelago of 316Km2. These
Islands have been well reported to feature both dysgly-
caemic and obesogenic characteristics. However the
local depression burden at a population level has never
been explored [24, 25]. These islands at the epicenter of
the Mediterranean region provide a unique opportunity
to explore the varying phenotypes and the relationships
between the different spectrum of glycaemic status and
the presence of depression at a population level. Other
Mediterranean countries, both in the Northern and the
Southern regions, can relate to these Islands’ characteris-
tics. The evidence-accrued here can be useful to both
public health officials and policy makers.
The aim of this study was to establish for the first time
the prevalence of depression and depressive symptoms
at population level, while addressing the hypothesis that
a link between depression and dysglycaemia exists within
the high risk dysglycaemic-obesogenic population. Dys-
glycaemia is a spectrum of abnormal plasma glucose
levels ranging from impaired fasting plasma glucose to
full-blown diabetes. The objectives included determining
the biological, psychological, socio-economic character-
istics of depression in accordance with the varying gly-
caemic status of the population. Additionally, to
establish the links between groups with differing gly-
caemic status, depression and depressive symptoms
while considering potential confounding factors includ-
ing age, sex and medical co-morbidities.
Method
Data collection
The University of Malta conducted a nationally repre-
sentative cross-sectional study between 2014 and 2016.
The detailed methodology of the health examination
study is found elsewhere [26]. Briefly, a single stage ran-
domized stratified (by age, sex and locality) sample was
obtained from a national register (n = 4000). The sample
population (18 to 70 years) represented approximately
1% of each Maltese town. Those that were pregnant,
were too ill to attend for the health examination or were
temporarily or permanently living abroad were excluded.
Participants were invited through an invitation letter
sent to their home address. Those accepting our invita-
tion were to attend their local peripheral governmental
clinic (health examination hub) during a preset weekend.
The health examination hub was set up in a different
town every weekend. This facilitated the attendance by
bringing the hub close to each participant’s residence.
An informed written consent was obtained from each
participant. Trained interviewers distributed a validated
demographic, social and medical co-morbidity (including
self-reported depression and type 2 diabetes) question-
naire. Participants were advised to bring a list of their
daily medication when they confirmed their appoint-
ment. This was listed on the questionnaire. In addition,
the questionnaire also included the PHQ-9 (patient
health questionnaire) as a tool for depressive symptoms
[27]. During the health examination, blood pressure (re-
peated three times), height, weight, waist circumference
and hip circumference measurements were recorded for
each participant. Participants had two blood samples
taken, one for fasting plasma glucose (FPG) and one for
lipid profile. Ethical and data protection approvals were
granted from the University of Malta Research Ethical
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Committee (UREC) and the Information and Data pro-
tection national commissioner respectively.
Study population
A participation response of 47.15% was obtained (n =
1861). A weighting factor was applied to each participant
according to the age, gender and locality in order to main-
tain national representativeness. The adjusted study popula-
tion represented 1% of the population. The total adjusted
population was of 3947 with a male predominance (n =
1998) and a median age of 45 years. The majority of the
study population lived within the highest density populated
district (Northern Harbour) and reported to be employed
with the highest education level up to secondary school.
Definitions
This study followed the PHQ-9 score definition used by
Katon et al. [28], where the total score and depression se-
verity were divided and defined as follows: 1–4 score as
“No depression”; 5–14 score as “Minor depression” and
15 to 27 score as “Major depression”. Those individuals
not previously aware of suffering from depression or
reporting not to be on anti-depression medication but
scoring > 14 in the PHQ-19 score, were considered as hav-
ing newly diagnosed depression [29]. The segment of the
study population reporting an established history of de-
pression, were considered as being aware of depression.
The combination of the population labelled as ‘aware of
depression’ with those ‘on medication’ and ‘newly diag-
nosed depression’ (PHQ-9 score > 14) sub-populations
were labeled as the global depression population.
The study population was subdivided into four glucose
regulatory subgroups. These represented a continuum of
glycaemic transition from normal to disordered glucose
metabolism. The four sub-groups were: (1) normogly-
caemia (NGR), (2) impaired fasting glucose (IFG), (3)
newly diagnosed diabetes mellitus (NDM) and (4)
known diabetes mellitus (KDM) subgroups. The subdiv-
ision was based on the fasting plasma glucose results ob-
tained during the health examination survey while
incorporating any self-reported history of diabetes melli-
tus and intake of oral hypoglycaemic agents. Those par-
ticipants obtaining a fasting plasma glucose (FPG) level
between 5.60–6.99 mmol/L (100.8–125.8 mg/dL) were
labeled as Impaired Fasting Glucose (IFG) while those
with a FPG > =7mmol/L (> = 126 mg/dL) were labeled
as Newly diagnosed diabetes mellitus (NDM), provided
they were not previously diagnosed as diabetics or were
on oral hypoglycaemic agents [30]. Those participants
falling within the IFG criteria range were offered an oral
glucose tolerance test (OGTT) two weeks after their ini-
tial examination [31]. Those undergoing the OGTT test
and obtaining a 2-h glucose level beyond 11.1 mmol/L
(199.8 mg/dL) were labelled also as Newly diagnosed
diabetes mellitus (NDM), while those that remained with
an FPG between 5.60–6.99 mmol/L (100.8–125.8 mg/dL)
but normal 2nd hour glucose level were labeled as Im-
paired Fasting Glucose (IFG). The small proportion of
individuals that fell within the “Impaired glucose toler-
ance” (IGT) range (i.e. 2nd hour glucose level between
7.8–11.1 mmol/L / 140.4 – 198mg/dL) all had their cor-
responding FPG within the IFG range and hence for the
scope of this study, were added to the IFG sub-
population. Similarly, those undergoing the OGTT and
obtaining a normoglycaemic profile were added to the
normoglycaemic sub-population.
The participants with a previous history of diabetes
mellitus or on oral hypoglycemic agents, irrespective of
their measured fasting plasma glucose, were labeled as
cases of Known diabetes mellitus (KDM). Those individ-
uals who did not fall within these glucose dysglycaemic
categories were considered to be Normoglycaemic
(NGR). The depression prevalence rate for each sub-
population was calculated.
Identifying newly diagnosed diabetics following a single
fasting blood glucose reading is of common practice in
population-based health examination surveys [32]. In fact, it
has been reported that this case definition is used in epi-
demiological studies and provides a good estimate of diabetes
prevalence. This is because on repeat testing, an approximate
75% of those previously tested and found to have an FPG ≥7
mmol/l had a confirmed clinical diabetes diagnosis [33, 34].
Statistical analysis
Descriptive and analytic analyses were performed to es-
tablish the phenotypic characteristics of the depression
sub-population with their corresponding glycemic status.
Categorical variables were statistically analyzed using
Chi squared testing while continuous variables were
tested using Mann-Whitney U test since the data did
not follow a normal distribution. A p-value of < 0.05 was
considered as significant.
The most common literature based biological (sex and
age), social habit (smoking), socioeconomic (education
level and occupation) and medical co-morbidities (his-
tory of coronary heart disease, myocardial infarction,
stroke, hypertension and anti-depressive medication)
factors associated with depression were considered dur-
ing the modeling analyses. Multivariate logistic regres-
sion analyses were performed while considering self-
reported depression, major depression symptoms and
global depression as the outcomes (respectively). The
normoglycaemic sub-population was considered as the
reference category.
Results
The global depression point prevalence for the entire
population was of 17.15% (CI 95%: 16.01–18.36) with a
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female preponderance (58.35% CI 95%: 54.59–62.00). On
a national level, a total of 58,345 adults between 18 to
70 years (n = 340,204) have been estimated to be suffer-
ing from global depression [35]. The study’s global de-
pression population (n = 677) was composed of 60.86%
(CI 95%: 57.13–64.46; n = 412) with self-reported depres-
sion while the remainder exhibited depressive symptoms
(PHQ-9 score > 14; n = 18) or were on medication but
claimed not to be aware that they suffered from depres-
sion (n = 247). The latter sub-group could include those
genuinely forgetful of having been once treated for de-
pression, those who were treated for depression but they
were never actually told about their diagnosis and those
who used off-label anti-depression medication for other
conditions (e.g. commonly Tricyclic depressants are used
in cases of chronic pain) [36].
The study population (n = 3947) was subcategorized
according to the glycaemic status. The majority of the
study population had a normoglycaemic status (66.25%
CI 95%: 64.76–67.71). Each glycaemic status was further
categorized into the different depression categories. This
was followed by estimating the prevalence for each de-
pression status according to each glycemic category, as
can be seen in Table 1. The known diabetes sub-group
featured the highest global depression (26.01%) preva-
lence when compared to the other glycaemic status. Of
note, this study did not identify any new depressive
symptoms within the diabetic status (both KDM and
NDM) sub-groups although a number of these individ-
uals were on medication but reported not to be aware of
any underlying depression. At a national level, an esti-
mated 37,422 adults between the ages of 18 and 20 years
could be normoglycaemic and have global depression
(11% CI 95%: 10.06–12.01 of study population). An esti-
mated 12,860 adults could have an impaired glucose and
global depression (3.78% CI 95% 3.23–4.42), while an
estimated 5613 adults could have known diabetes and
global depression (1.65% CI 95%: 1.3–2.1).
The majority of the ‘global depression sub-population’
was made up of participants reporting to suffer from de-
pression that was diagnosed by a physician. It was there-
fore considered as appropriate to use this sub-population
to identify the phenotypic characteristics of depression at
a population level, are shown in Table 2. It was observed
that as the glycaemic status shifted from normoglycaemic
to diabetes, the median age, the fasting plasma glucose
(FPG) and the body mass index (BMI) increased. The edu-
cational levels also showed a decline (a decrease in num-
ber of education years) with this glycaemic shift. The lipid
profile was observed to increase as the glycaemic status
shifted from normoglycaemic to newly diagnosed diabetes.
Of note, the known diabetes sub-population exhibited a
better lipid profile. This follows the fact that all diagnosed
diabetics are started on lipid lowering agents as part of the
Table 1 Distribution of the different depression categories by glycemic status
NGR n = 2615 IFG n = 925 NDM n = 158 KDM n = 249
[Male n = 1164; Female n =
1451]
[Male n = 563; Female n =
362]
[Male n = 103; Female n =
55]




N (%; CI 95%) N (%; CI 95%) N (%; CI 95%) N (%; CI 95%)
Self-reported
Total 262 (10.02%; 8.92–11.23) 91 (9.84%; 8.07–11.93) 17 (10.76%; 6.74–16.64) 42 (16.87%; 12.70–22.04)
Males 78 (6.70%; 5.40–8.29) 47 (8.35%; 6.32–10.94) 11 (10.68%; 5.91–18.28) 22 (13.10%; 8.74–19.10)
Females 184 (12.68%; 11.06–14.50) 44 (12.15%; 9.16–15.95) 6 (10.91%; 4.74–22.18) 20 (24.69%; 16.52–35.15)
Unaware but on Rx
Total 159 (6.08%; 5.22–7.06) 53 (5.73%; 4.40–7.43) 12 (7.59%; 4.28–12.92) 23 (9.24%; 6.18–13.53)
Males 71 (6.10%; 4.86–7.63) 25 (4.44%; 3.00–6.50) 8 (7.77%; 3.78–14.79) 18 (10.71%; 6.81–16.38)
Females 88 (6.06%; 4.94–7.42) 28 (7.73%; 5.37–10.99) 4 (7.27%; 2.38–17.75) 5 (6.17%; 2.33–13.98)
Unaware with PHQ-9 score > 14
Total 13 (0.50%; 0.28–0.86) 5 (0.54%; 0.19–1.30) 0 0
Males 2 (0.17%; 0.01–0.67) 0 0 0
Females 11 (0.76%; 0.41–1.37) 5 (0.34%; 0.12–0.83) 0 0
Global depression
Total 434 (16.60%; 15.22–18.07) 149 (16.11%; 13.88–18.62) 29 (18.25%; 13.05–25.16) 65 (26.10%; 21.03–31.91)
Males 151 (12.97%; 11.16–15.03) 72 (12.79%; 10.27–15.81) 19 (18.45%; 12.06–27.11) 40 (23.81; 17.97–30.82)
Females 283 (19.50%; 17.55–21.62) 77 (21.27%; 17.36–25.79) 10 (18.18%; 9.99–30.53) 25 (30.86%; 21.83–41.63)
Abbreviations: NGR Normoglycaemiia, IFG Impaired fasting glocuse, NDM Newly diagnosed diabetes, KDM Known diabetes, CI Confidence Interval, Rx Treatment
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diabetic management regimen at the general hospital
(where free medication is also authorised for all diabetics).
In fact, 65% (n = 61) of the diabetic population with a ‘glo-
bal depression’ label was on statin therapy.
Multivariate logistic regression analyses were per-
formed with (i) self-reported depression, (ii) depressive
symptoms cutoff score > 14 (iii) and global depression as
the outcome respectively, while adjusting for sex, age,
smoking, socio-economic factors and medical comorbid-
ities. Among those with a dysglycaemic status, only
those with a previously known diabetes diagnosis (KDM)
were associated with a two-fold increased risk of having
depression (self-reported), as seen in Table 3. The KDM
sub-population also exhibited a two-fold increased risk
of having ‘general depression’ although this difference
held a borderline significance (p = 0.06).
On considering the links between the potential co-
founding factors within the depression sub-groups, fe-
males had an 85% increased risk of having self-reported
depression (OR 1.85 CI95%: 1.26–2.71, p = < 0.01) and a
61% increased risk of having global depression (OR 1.61
CI95%: 1.07–2.43, p = 0.02). Those that smoked ap-
peared to have a 99% increased risk of having a self-
reported depression (OR 1.99 CI 95%: 1.42–2.79, p = <
0.01) as well as a global depression status (OR 1.99
1.38–2.85, p = < 0.01). As expected, a medical history of
coronary heart disease, hypertension and stroke also in-
creased the associated risk of having depression. Inter-
estingly, a young age was associated with having severe
depressive symptoms (PHQ-9 > 14; Age OR 0.90 CI 95%
0.85–0.95, p = < 0.01).
Discussion
Diabetes mellitus and depression are both contributing
to a growing global burden of disease, projected to in-
crease in the upcoming years. In fact, the World Health
Organization (WHO) predicted that by the year 2020,
depression will rank as the second largest global burden
Table 2 Phenotypic characteristics of the global depression population according to each glycaemic sub-population
Global Depression p-
valuen NGR IFG NDM KDM
434 149 29 65
Median Age in years (IQR) 41 (27) 54 (18) 63 (8) 64 (11) < 0.01
Median BMI in Kg/m2 (IQR) 26.40 (5.80) 28.90 (7.96) 28.72 (5.04) 30.86 (6.08) < 0.01
Median FBG in mmol/L (IQR) 5.07 (0.48) 5.85 (0.43) 8.05 (1.91) 8.50 (3.61) < 0.01
Median LDL-C in mmol/L (IQR) 3.21 (1.09) 3.32 (1.14) 3.08 (1.45) 2.41 (1.23) < 0.01
Median HDL-C in mmol/L (IQR) 1.49 (0.73) 1.39 (0.54) 1.15 (0.51) 1.26 (0.37) < 0.01
Median Triglycerides in mmol/L (IQR) 0.92 (0.54) 1.06 (0.99) 1.68 (0.96) 1.03 (0.57) < 0.01
Median Total cholesterol in mmol/L (IQR) 5.23 (1.37) 5.50 (1.24) 5.28 (1.19) 4.38 (1.50) < 0.01
Education in years < 0.01
< =10 years n (%) 59 (13.59) 43 (28.86) 15 (51.72) 35 (53.85)
11–13 years n (%) 270 (62.21) 78 (52.35) 10 (34.48) 26 (40)
> =14 years n (%) 105 (24.19) 28 (18.79) 4 (13.79) 4 (2.46)
Current smoking n (%) 187 (43.09) 38 (25.50) 14 (48.28) 21 (32.31) 0.06
Occupation < 0.01
Employed n (%) 291 (67.05) 73 (48.99) 11 (37.93) 15 (23.08)
Unemployed n (%) 9 (2.07) 5 (3.36) 0 0
Student n (%) 18 (4.15) 11 (7.38) 0 0
Retired n (%) 32 (7.37) 36 (24.16) 13 (44.83) 32 (49.23)
Domestic work n (%) 84 (19.35) 24 (16.11) 5 (17.24) 18 (27.69)
Medical history
Coronary heart disease n (%) 25 (5.76) 6 (4.03) 8 (27.59) 14 (21.54) 0.01
Myocardial infarction n (%) 18 (4.15) 6 (4.03) 0 6 (9.23) 0.41
Stroke n (%) 17 (3.92) 6 (4.03) 8 (27.59) 0 0.12
Hypertension n (%) 76 (17.51) 52 (34.90) 21 (72.41) 43 (66.15) < 0.01
IQR = Interquartile range
p-value: Kruskal-Wallis test for Median values and Chi test for categorical variables
% representing the proportion out of the respective glycaemic status
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while the International Diabetes Federation (IDF) pro-
jected a 51% diabetes prevalence increase across the
world by the year 2045 [37, 38]. These projections were
computed before the onset of COVID-19 pandemic. The
current global pandemic has had great implications on
global mental health as well as on the management and
care treatment of diabetes [39, 40]. Hence, it is expected
that both diabetes and depression will have a far higher
global burden impact than previously projected. This
study was conducted in the pre-COVID-19 era, but it is
Table 3 Multivariate logistic regression analyses with self-reported depression, major depression symptoms and global depression as
the outcome
Self-reported depression PHQ-9 major depression (score > 14) Global depression
Odd’s ratio (95% CI) p-value Odd’s ratio (95% CI) p-value Odd’s ratio (95% CI) p-value
Glucose status:
NGR Reference Reference Reference
IFG 1.05 (0.71–1.55) 0.81 1.633 (0.28–9.40) 0.58 0.82 (0.54–1.25) 0.35
NDM 0.52 (0.21–1.33) 0.18 0.87 (0.60–4.97) 1.00 0.59 (0.23–1.51) 0.27
KDM 2.36 (1.12–4.96) 0.02 0.95 (0.50–2.39) 1.00 2.16 (0.97–4.80) 0.06
Adjusted Cofounding factors:
Femalea 1.85 (1.26–2.71) < 0.01 1.59 (0.45–5.56) 0.47 1.61 (1.07–2.43) 0.02
Age (years) 0.99 (0.98–1.01) 0.48 0.90 (0.85–0.95) < 0.01 1.00 (0.98–1.01) 0.64
BMI (Kg/m2) 1.00 (0.97–1.03) 0.81 1.06 (0.98–1.14) 0.13 1.00 (0.97–1.03) 0.99
FBG (mmol/L) 1.03 (0.92–1.15) 0.62 1.31 (0.26–6.44) 0.74 1.03 (0.92–1.15) 0.59
LDL-C (mmol/L) 0.64 (0.18–2.24) 0.49 0.36 (0.01–18.43) 0.77 0.72 (0.23–2.29) 0.58
HDL-C (mmol/L) 0.36 (0.10–1.26) 0.11 0.27 (0.01–48.54) 0.71 0.40 (0.12–1.31) 0.13
Triglycerides (mmol/L) 0.70 (0.41–1.19) 0.19 0.49 (0.02–10.77) 0.65 0.73 (0.44–1.20) 0.21
Total cholesterol (mmol/L) 2.15 (0.63–7.34) 0.22 3.12 (0.01–44.34) 0.75 2.04 (0.66–6.33) 0.22
Education in years
< =10 years 1.90 (1.05–3.45) 0.04 0.37 (0.22–13.98) 1.00 1.74 (0.93–3.29) 0.09
11–13 years 1.73 (1.08–2.77) 0.02 0.61 (0.44–25.88) 1.00 1.62 (0.98–2.66) 0.06
> =14 years Reference Reference Reference
Current smoking 1.99 (1.42–2.79) < 0.01 1.97 (0.70–5.53) 0.20 1.99 (1.38–2.85) < 0.01
Occupation
Employed 0.71 (0.45–1.11) 0.13 0.20 (0.06–0.71) 0.01 0.75 (0.46–1.23) 0.26
Unemployed 1.90 (0.65–5.52) 0.24 3.72 (0.56–24.81) 0.18 1.14 (0.31–4.21) 0.84
Student 0.24 (0.05–1.11) 0.07 1.45 (0.23–7.89) 1.00 0.33 (0.07–1.58) 0.17
Retired 1.18 (0.70–1.97) 0.54 1.08 (0.18–6.64) 0.93 1.20 (0.69–2.10) 0.53
Domestic work Reference Reference Reference
Medical history
Coronary heart diseaseb 2.90 (1.35–6.21) < 0.01 1.20 (0.45–13.67) 1.00 3.43 (1.56–7.53) < 0.01
Myocardial infarctionc 0.75 (0.29–1.93) 0.55 1.78 (0.98–16.98) 1.00 0.80 (0.31–2.09) 0.65
Stroked 3.03 (1.13–8.09) 0.03 1.29 (0.67–18.32) 1.00 3.42 (1.19–9.84) 0.02
Hypertensione 1.44 (1.00–2.06) 0.05 1.06 (0.33–3.36) 0.92 1.31 (0.89–1.93) 0.17
Anti-depression treatmentf 1.12 (0.74–1.70) 0.59 0.47 (0.15–1.42) 0.18 1.38 (0.60–15.89) 1.00
NGR Normoglycaemia
IFG Impaired fasting glucose
NDM Newly diagnosed diabetes
KDM Known diabetes
aMale as reference
b No history coronary heart disease as the reference category
c No history myocardial infarction as the reference category
d No history stroke history as the reference category
e No history of hypertension as the reference category
f No history of anti-depression treatment as the reference category
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the first national study to cover both diseases. It pro-
vides essential data that can be utilized by local public
health authorities as well as by other Mediterranean
countries.
The established depression point prevalence in this
study population was higher than the average pooled
point prevalence across both European and African con-
tinents [41]. In fact, the 2017 Global Burden of Diseases
(GBD) study reported that depressive disorders attrib-
uted to 6.1% of Malta’s health disability in terms of dis-
ability adjusted life years (DALYs), while diabetes
attributed to 30.2% of DALYs [42]. Hence, it stands to
reason that the previously known diabetes sub-
population had the highest depression prevalence among
all glycaemic categories, as it was previously reported by
other studies [8, 43, 44]. A link was also established in
this study between known diabetes and self-reported de-
pression. This further confirms the already established
link between both diseases [8, 43, 44]. Diabetes has
already been established to be an attributor for the de-
velopment of cardiovascular diseases [45]. This study
further supports these relationships as a positive associa-
tions between depression and cardiovascular diseases
were observed. Of interest known diabetes was only as-
sociated with self-reported depression and not with the
presence of depressive symptoms, which coincides with
the findings of a Finnish Study conducted in 2007 [10].
A probable explanation is that diagnosed diabetic indi-
viduals tend to be already engaged in a healthy lifestyle
management plan including weight management as well
as having a prescription for both anti-diabetic and anti-
dyslipidaemic medication [30, 46]. These management
plans may create stress and anxiety for the individual,
resulting in depression [47]. Furthermore, it was re-
ported that those with multi-factorial treatment plans
showed higher distress levels than for those with less in-
tensive treatments [48]. Due to the diabetic management
intervention plans, these diabetic individuals are ex-
pected to have better controlled blood glucose, better
lipid profile levels and more normalized body mass indi-
ces. In fact, the previously diagnosed diabetics in this
study exhibit a controlled lipid profile but poor glucose
and body mass control. Conversely, individuals with dia-
betes who reported depressive features had a poor gly-
caemic control and are therefore susceptible to
developing other comorbidities [44, 49]. This poor gly-
caemic control could be related to the effect of depres-
sion on the individual’s diabetes self-care including
maintaining a healthy diet, undertaking physical activity
and the adherence to medication [50, 51].
Interestingly this study identified that being on anti-
depression treatment was not linked with depression or
depression symptoms, which contradicts the literature
[10]. Although it is recommended that further research
is conducted, this finding could be the result of optimal
treatment resulting in a regression relationship between
the disease and its symptoms. Another potential reason
could be that although the PHQ-9 is an internationally
validated tool [27], it has never been validated within the
Maltese population. This might have led to pitfalls in its
screening ability for depression symptoms within this
population. Another interesting finding was the positive
link between young adult age and depression symptoms,
which goes against previously reported late-life and de-
pression links [52]. However, this study’s link was only sig-
nificant with depression symptoms which could be
explained by the fact that young adults are typically faced
by peer and media pressures which put stress on their
self-esteem and confidence leading to potential depressive
symptoms [53]. As one gets older, these pressures may no
longer play a significant psychological impact as before.
Also, there is a higher tendency for an affected person (in
the older age group) to seek medical aid and starts follow-
ing a psychological or medical therapy [54].
On a population level, this study observed the highest
depression prevalence rate within the normoglycaemic
population that makes up the majority of the total popu-
lation. This finding is of public health concern, since al-
though depression is linked with diabetes, a large
proportion of the population without dysglycaemia was
actually observed to have mental health issues. Low so-
cioeconomic status, psychological stress and behavioural
characteristics might be contributing to this finding, al-
though further research is recommended. However,
these findings put forward the recommendation that as-
sessment for depressive symptoms might be considered
as part of routine check-ups at primary health level, irre-
spective of the individual’s glycaemic status, with special
attention to young adults. Clinical tools are available that
can be easily implemented by physicians as part of their
routine work-up [14, 31, 32]. It is recommended that a
survey involving few general practitioners’ practices is
conducting to reproduce this study’s findings within the
Maltese population.
Increased advocacy regarding mental health should
empower individuals across all ages to seek medical and
psychological help if the need arises. In fact, recently “A
mental health strategy 2020- 2030” has been imple-
mented in Malta in order to reduce the burden and
impact of such disease on the population [55].
Strengths and limitations
This is the first study conducted at a population level
within Malta, targeting depression and dysglycaemia.
The study protocol was based on the European Health
Examination protocol and hence comparative analyses
could be performed.
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A number of limitations were present. A response rate
of 47.15% was obtained which was in keeping with a pre-
vious pilot Maltese health examination survey and other
health examination surveys across Europe [56, 57]. In re-
cent years it has been noted that a steep decline in par-
ticipation rates is occurring due to the increase in the
amount of available epidemiological surveys and invasive
procedures [58]. Hence, the respondent data has been
weighted to reflect the origin sample population thereby
preserving representation.
The depression data was self-reported, so that human
recall error and bias may have been present. Depression
symptoms were determined using the PHQ-9 tool,
which is a self-reported tool that may miss less severe
cases of depression [33]. For the purposes of this study,
only major depressive symptoms were considered. This
might have had an effect on the overall findings. Add-
itionally, this tool was never validated for the Maltese
population, hence screening results may not have been
optimal. This study was based on cross-sectional data
and subject to information bias. The establishment of
chronological links between cause and effects is not pos-
sible. The glycaemic status was based on one single fast-
ing plasma glucose reading and medical history. Only
those with IFG were offered an OGTT. Since an OGTT
was not offered as the baseline test to everyone, a pro-
portion of dysglycaemic individuals might have been
missed and therefore this acts as a limitation.
Conclusion
The study confirms the strong link between diabetes and
depression in a high risk dysglycaemic population. How-
ever, of public health importance is the high depression
occurrence within the normoglycaemic sub-population
which make up the majority of the total Maltese popula-
tion. In order to reduce the impact of mental health on
the population, physicians should consider implementing
depression screening clinical tools as part of their rou-
tine health check-ups, irrespective of the glycaemic
status of their patients.
Abbreviations
BMI: Body mass index; CI: Confidence interval; DALYs: Disability adjusted life
years; FPG: Fasting plasma glucose; IDF: International Diabetes Federation;
IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance;
IQR: Interquartile range; GBD: Global Burden of Disease; KDM: Known
diabetes mellitus; NDM: Newly diagnosed diabetes mellitus;
NGR: Normoglycaemia; OGTT: Oral glucose tolerance test; OR: Odds ratio;
PHQ-9: Patient health questionnaire; WHO: World Health Organization
Acknowledgements
The authors are extremely grateful for the strong support forthcoming from
the University of Malta (through the Medical School and Research Innovative
Development Trust department) and from the Alfred Mizzi Foundation as
major sponsors, as well as that of a host of others, including Atlas Health
Insurance (Malta). The in-kind support and encouragement of the Parliamen-
tary Secretariat for Health of the Government of Malta is also gratefully
acknowledged.
Authors’ contributions
SC analyzed and interpreted the patient data. JM reviewed and proved the
final manuscript. The authors read and approved the final manuscript.
Funding
Funding was obtained from the University of Malta, Alfred Mizzi Foundation
and Atlas Insurance (Malta). Funding had no role in the design of the study,
analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Ethics approval and consent to participate
Ethics approval was granted by the University of Malta Research Ethics




The authors declare that they have no competing interests.
Author details
1Department of Anatomy, Faculty of Medicine and Surgery, University of
Malta, Msida, MSD 2080, Malta. 2Department of Public Health, Faculty of
Medicine and Surgery, University of Malta, Msida, Malta.
Received: 16 December 2019 Accepted: 27 October 2020
References
1. Lépine J-P, Briley M. The increasing burden of depression. Neuropsychiatr
Dis Treat. 2011;7:3–7.
2. Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe—a
critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;
15:357–76.
3. Freeman A, Tyrovolas S, Koyanagi A, et al. The role of socio-economic status
in depression: results from the COURAGE (aging survey in Europe). BMC
Public Health. 2016;16:1098.
4. Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary
artery disease in men: the precursors study. Arch Intern Med. 1998;158:
1422–6.
5. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of
depressive symptoms on adherence, function, and costs. Arch Intern Med.
2000;160:3278–85.
6. Ohira T, Iso H, Satoh S, et al. Prospective study of depressive symptoms and
risk of stroke among japanese. Stroke. 2001;32:903–8.
7. Salinero-Fort MA, Gómez-Campelo P, San Andrés-Rebollo FJ, et al.
Prevalence of depression in patients with type 2 diabetes mellitus in Spain
(the DIADEMA Study) : results from the MADIABETES cohort. BMJ Open.
2018;8:e020768.
8. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid
depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:
1069–78.
9. Fisher L, Skaff MM, Mullan JT, et al. Clinical depression versus distress
among patients with type 2 diabetes: not just a question of semantics.
Diabetes Care. 2007;30:542–8.
10. Mantyselka P, Korniloff K, Saaristo T, et al. Association of Depressive
Symptoms with Impaired Glucose Regulation, screen-detected, and
previously known type 2 diabetes: findings from the Finnish D2D survey.
Diabetes Care. 2011;34:71–6.
11. Nouwen A, Nefs G, Caramlau I, et al. Prevalence of depression in individuals
with impaired glucose metabolism or undiagnosed diabetes: a systematic
review and meta-analysis of the European depression in diabetes (EDID)
research consortium. Diabetes Care. 2011;34:752–62.
12. Ortega-Azorín C, Sorlí JV, Asensio EM, et al. Associations of the FTO
rs9939609 and the MC4R rs17782313 polymorphisms with type 2 diabetes
are modulated by diet, being higher when adherence to the Mediterranean
diet pattern is low. Cardiovasc Diabetol. 2012;11:137.
Cuschieri and Mamo Archives of Public Health          (2020) 78:111 Page 8 of 9
13. Greco M, Chiefari E, Montalcini T, et al. Early effects of a Hypocaloric,
Mediterranean Diet on Laboratory Parameters in Obese Individuals.
Mediators Inflamm. 2014;2014:1–8.
14. Argyropoulos K, Machini E. Adherence to Mediterranean diet and risk of
depression later in life. A cross sectional study in East Attica, Greece. Glob
Psychiatry; 2. Epub ahead of print 2019. https://doi.org/10.2478/gp-2019-0012.
15. Skarupski KA, Tangney CC, Li H, et al. Mediterranean diet and depressive
symptoms among older adults over time. J Nutr Health Aging. 2013;17:441–5.
16. Sánchez-Villegas A, Ruíz-Canela M, Gea A, et al. The association between the
Mediterranean lifestyle and depression. Clin Psychol Sci. 2016;4:1085–93.
17. Sánchez-Villegas A, Delgado-Rodríguez M, Alonso A, et al. Association of the
Mediterranean Dietary Pattern with the incidence of depression. Arch Gen
Psychiatry. 2009;66:1090.
18. Vidal-Peracho C, Tricás-Moreno JM, Lucha-López AC, et al. Adherence to
Mediterranean diet pattern among Spanish adults attending a medical
Centre: nondiabetic subjects and type 1 and 2 diabetic patients. J Diabetes
Res. 2017;2017:1–11.
19. Rojo-Martínez G, Valdés S, Soriguer F, et al. Incidence of diabetes mellitus in
Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10:
2765.
20. Cuschieri S. The diabetes epidemic in Malta. South East Eur J Public Heal.
Epub ahead of print 19 February 2020. DOI: https://doi.org/10.4119/seejph-
3322.
21. Moradi-Lakeh M, Forouzanfar MH, El Bcheraoui C, et al. High fasting plasma
glucose, diabetes, and its risk factors in the eastern Mediterranean region,
1990-2013: findings from the global burden of disease study 2013. Diabetes
Care. 2017;40:22–9.
22. Marre M. The role of scientific societies in the sharing of expertise The
Mediterranean Group for the Study of Diabetes (MGSD) and the study on
gestational diabetes in the Mediterranean region. Medicographia; 33, https://
www.medicographia.com/2011/07/focus/ (2011, Accessed 31 July 2020).
23. Piscopo S. Socio-ecological factors influencing food choices and behaviours
of Maltese primary school children. The University of Birmingham, http://
etheses.bham.ac.uk/861/1/Piscopo04PhD.pdf (2004, Accessed 14 January
2019).
24. Cuschieri S, Vassallo J, Calleja N, et al. The diabesity health economic crisis-
the size of the crisis in a European island state following a cross-sectional
study. Arch Public Heal. 2016;74:52.
25. Cuschieri S, Mamo J. Malta: Mediterranean diabetes hub – a journey
through the years. Malta Med J. 2014;26(03):27–31.
26. Cuschieri S, Vassallo J, Calleja N, et al. Diabetes, pre-diabetes and their risk
factors in Malta: A study profile of national cross-sectional prevalence study.
Glob Heal Epidemiol Genomics; 1. Epub ahead of print 2016. DOI:
https://doi.org/10.1017/gheg.2016.18.
27. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16:606–13.
28. Katon W, von Korff M, Ciechanowski P, et al. Behavioral and clinical factors
associated with depression among individuals with diabetes. Diabetes Care.
2004;27:914–20.
29. Mitchell AJ, Yadegarfar M, Gill J, et al. Case finding and screening clinical
utility of the patient health questionnaire (PHQ-9 and PHQ-2) for depression
in primary care: a diagnostic meta-analysis of 40 studies. Br J Psychiatry
Open. 2016;2:127–38.
30. American Diabetes Association. Classification and Diagnosis of Diabetes.
Diabetes Care. 2016;39 Suppl 1:S13–22.
31. Cuschieri S, Grech S. Assessing impaired fasting blood glucose criteria for
high-risk dysglycaemic populations: an experience from a European
population state. J Diabetes Metab Disord. 2020:1–7. https://doi.org/10.
1007/s40200-020-00563-8.
32. World Health Organization. Global action plan for the prevention and control
of noncommunicable diseases 2013–2020. World Heal Organ. 2013.
33. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of
glucose, specific insulin and proinsulin concentrations measured by two
oral glucose tolerance tests in a general Caucasian population: the Hoorn
study. Diabetologia. 1996;39:298–305.
34. Christensen JO, Sandbaek A, Lauritzen T, et al. Population-based stepwise
screening for unrecognised type 2 diabetes is ineffective in general practice
despite reliable algorithms. Diabetologia. 2004;47:1566–73.
35. National Statistics Office (NSO). Regional statistics Malta 2020 edition,
https://nso.gov.mt/en/publicatons/Publications_by_Unit/Documents/02_
Regional_Statistics_(Gozo_Office)/2020/Regional_Statistics_Malta-2020
Edition.pdf. (2020, Accessed 13 June 2020).
36. Patten SB. Recall bias and major depression lifetime prevalence. Soc
Psychiatry Psychiatr Epidemiol. 2003;38:290–6.
37. World Health Organization. The world health report 2001: Mental health:
now understanding, new hope. Geneva: World Health Organization; 2001.
38. International Diabetes Federation. IDF Diabetes Atlas 9th Edn. Brussels,
Belgium, http://www.diabetesatlas.org (2019).
39. Torales J, O’Higgins M, Castaldelli-Maia JM, et al. The outbreak of COVID-19
coronavirus and its impact on global mental health. Int J Soc Psychiatry.
2020;66:317–20.
40. Cuschieri S, Grech S. COVID-19 and diabetes: the why, the what and the
how. J Diabetes Complicat. 2020;34:107637. https://doi.org/10.1016/j.
jdiacomp.2020.107637.
41. Lim GY, Tam WW, Lu Y, et al. Prevalence of depression in the community
from 30 countries between 1994 and 2014. Sci Rep. 2018;8:2861.
42. Institute for Health Metrics and Evaluation (IHME). Malta profile. Seattle, WA:
IHME, University of Washington, http://www.healthdata.org/malta (2018,
Accessed 15 February 2020).
43. Mommersteeg PMC, Herr R, Pouwer F, et al. The association between
diabetes and an episode of depressive symptoms in the 2002 world health
survey: an analysis of 231 797 individuals from 47 countries. Diabet Med.
2013;30:e208–14.
44. Egede LE, Ellis C. Diabetes and depression: global perspectives. Diabetes Res
Clin Pract. 2010;87:302–12.
45. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology,
biological mechanisms, treatment recommendations and future research.
World J Diabetes. 2015;6:1246–58.
46. Eldor R, Raz I. American Diabetes Association indications for statins in
diabetes: is there evidence? Diabetes Care. 2009;32(Suppl 2):S384–91.
47. Engum A. The role of depression and anxiety in onset of diabetes in a large
population-based study. J Psychosom Res. 2007;62:31–8.
48. Ismail K, Moulton CD, Winkley K, et al. The association of depressive
symptoms and diabetes distress with glycaemic control and diabetes
complications over 2 years in newly diagnosed type 2 diabetes: a
prospective cohort study. Diabetologia. 2017;60:2092–102.
49. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic
control: a meta-analytic review of the literature. Diabetes Care. 2000;23:934–42.
50. Lin EHB, Katon W, Von Korff M, et al. Relationship of depression and
diabetes self-care, medication adherence, and preventive care. Diabetes
Care. 2004;27:2154–60.
51. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment
nonadherence: A meta-analysis. Diabetes Care. 2008;31:2398–403.
52. Blackburn P, Wilkins-Ho M, Wiese B. Depression in older adults: diagnosis and
management | British Columbia medical journal. BC Med J. 2017;59:171–7.
53. Keles B, McCrae N, Grealish A. A systematic review: the influence of social
media on depression, anxiety and psychological distress in adolescents. Int
J Adolesc Youth. 2020;25:79–93.
54. Institute of Medicine (US) Committee on the Future Health Care Workforce
for Older. Health Status and Health Care Service Utilization. National
Academies Press (US), https://www.ncbi.nlm.nih.gov/books/NBK215400/
(2008, Accessed 9 August 2020).
55. Office of the Deputy Prim Minster and Minister For Health. Building
Resilience Transforming Services - A Mental Health Strategy For Malta 2020–
2030, https://deputyprimeminister.gov.mt/en/Documents/National-Health-
Strategies/Mental_Health_Strategy_EN.pdf (2018, Accessed 3 August 2020).
56. Directorate for Health Information and Research. The European Health
Examination Survey Pilot Study 2010. 2012.
57. Mindell JS, Giampaoli S, Goesswald A, et al. Sample selection, recruitment and
participation rates in health examination surveys in Europe – experience from
seven national surveys. BMC Med Res Methodol. 2015;15:78.
58. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann
Epidemiol. 2007;17:643–53.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cuschieri and Mamo Archives of Public Health          (2020) 78:111 Page 9 of 9
